Original Article
Copyright ©2010 Baishideng.
World J Gastroenterol. Jun 7, 2010; 16(21): 2638-2647
Published online Jun 7, 2010. doi: 10.3748/wjg.v16.i21.2638
Table 5 Patients’ baseline characteristics and outcome at 6 mo
VariableViusid (n = 30)
Placebo (n = 30)
P value1
Before treatmentAfter treatmentP valueBefore treatmentAfter treatmentP value
Body mass index (kg/m2)25.6 ± 0.725.7 ± 0.70.9226 ± 0.727.2 ± 0.60.080.12
Hemoglobin (g/L)125.8 ± 1.4125.2 ± 2.10.74132.2 ± 2.7135.6 ± 3.10.090.13
Alkaline phosphatase (mmol/L)217.2 ± 12206.1 ± 150.49217.1 ± 13211.4 ± 130.690.80
ALT (IU/L)67.6 ± 7.665.1 ± 9.90.6867.7 ± 8.463.5 ± 60.380.82
AST (IU/L)56 ± 757.7 ± 9.10.8162.7 ± 7.653.9 ± 6.50.110.24
Fasting plasma glucose (mmol/L)5 ± 0.14.8 ± 0.20.175.6 ± 0.45.4 ± 0.50.690.91
Creatinine (mmol/L)79.4 ± 2.875.7 ± 2.40.0683.3 ± 3.677.7 ± 30.170.67
γ-glutamyltransferase (IU/L)72.7 ± 1340.8 ± 6.10.00184.1 ± 1474.4 ± 100.560.002
Albumin (g/L)47.4 ± 0.546.6 ± 0.80.4346.5 ± 0.946.1 ± 10.720.79
Bilirubin (mmol/L)12.1 ± 0.0811.9 ± 0.070.9113.8 ± 0.0714.3 ± 0.080.790.67
Uric acid (mmol/L)257 ± 16.8198 ± 13.80.01276 ± 13.4267 ± 180.660.04